secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001193125-23-300412
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus appoints Robert Claypoole as President and CEO effective Jan 10, 2024
-------------------------------------------------------------------------------

- Claypoole appointed President and CEO effective Jan 10, 2024, succeeding interim CEO Anthony Bihl.
- Compensation: $800k base, 100% bonus target, $750k sign-on cash, 375k RSUs and 850k options.
- Claypoole previously EVP at Mölnlycke Health Care, leading $1.2B wound care; also held senior roles at Medtronic and Covidien.
- Company reaffirms full year financial guidance previously announced on November 7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/d448507d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-300412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer